Knut Håkon Hole

  • Consultant, researcher; MD, PhD
  • +47 22 93 58 90
 

Publications 2024

Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2024)
Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
J Pathol, 264 (3), 270-283
DOI 10.1002/path.6344, PubMed 39329425

Publications 2023

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer, 152 (10), 2166-2173
DOI 10.1002/ijc.34448, PubMed 36715014

Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
Cancers (Basel), 15 (18)
DOI 10.3390/cancers15184662, PubMed 37760629

Reijnen JS, Ryg U, Marthinsen JB, Schönhardt I, Seierstad T, Hole KH (2023)
Monoparametric high-resolution diffusion weighted MRI as a possible first step in an MRI-directed diagnostic pathway for men with suspicion of prostate cancer
Front Oncol, 13, 1102860
DOI 10.3389/fonc.2023.1102860, PubMed 36798813

Skingen VE, Hompland T, Fjeldbo CS, Salberg UB, Helgeland H, Ragnum HB, Aarnes EK, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2023)
Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
Radiother Oncol, 188, 109875
DOI 10.1016/j.radonc.2023.109875, PubMed 37640161

Switlyk MD, Hopland A, Reitan E, Sivanesan S, Brennhovd B, Axcrona U, Hole KH (2023)
Multiparametric Magnetic Resonance Imaging of Penile Cancer: A Pictorial Review
Cancers (Basel), 15 (22)
DOI 10.3390/cancers15225324, PubMed 38001583

Switlyk MD, Hopland A, Sivanesan S, Brennhovd B, Ottosson F, Berner K, Axcrona U, Hole KH (2023)
Multi-parametric MRI without artificial erection for preoperative assessment of primary penile carcinoma: A pilot study on the correlation between imaging and histopathological findings
Eur J Radiol Open, 10, 100478
DOI 10.1016/j.ejro.2023.100478, PubMed 36793771

Publications 2022

Ryg U, Seierstad T, Nilsen LB, Hellebust TP, Djupvik LH, Gustafson H, Hydal J, Kishan AU, Hole KH, Lilleby W (2022)
A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome
Front Oncol, 12, 861127
DOI 10.3389/fonc.2022.861127, PubMed 35463376

Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2022)
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
Br J Cancer, 127 (2), 321-328
DOI 10.1038/s41416-022-01782-x, PubMed 35332267

Publications 2021

Hernes E, Revheim ME, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Seierstad T (2021)
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis
PET Clin, 16 (2), 147-165
DOI 10.1016/j.cpet.2020.12.001, PubMed 33648661

Hole KH, Tulipan AJ, Reijnen JS, Hernes E, Vlatkovic L, Lie AK, Revheim ME, Seierstad T (2021)
Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Am J Nucl Med Mol Imaging, 11 (5), 387-394
PubMed 34754609

Hopland OA, Fosså SD, Ottosson F, Brennhovd B, Svindland A, Hole KH, Hernes E, Eri LM, Diep LM, Berge V (2021)
Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience
Scand J Urol, 55 (4), 287-292
DOI 10.1080/21681805.2021.1946135, PubMed 34196594

Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621

Reijnen JS, Marthinsen JB, Tysland AO, Müller C, Schönhardt I, Andersen E, Seierstad T, Hole KH (2021)
Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital
Abdom Radiol (NY), 46 (12), 5639-5646
DOI 10.1007/s00261-021-03249-8, PubMed 34417637

Revheim ME, Hole KH, Mo T, Bruland ØS, Reitan E, Julsrud L, Seierstad T (2021)
Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors
Acta Radiol, 63 (8), 995-1004
DOI 10.1177/02841851211027389, PubMed 34171968

Seierstad T, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Revheim ME, Hernes E (2021)
18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review
PET Clin, 16 (2), 167-176
DOI 10.1016/j.cpet.2020.12.012, PubMed 33648662

Tulipan AJ, Salberg UB, Hole KH, Vlatkovic L, Aarnes EK, Revheim ME, Lyng H, Seierstad T (2021)
Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer
Am J Nucl Med Mol Imaging, 11 (4), 250-259
PubMed 34513278

Publications 2020

Deek M, Lilleby W, Vaage V, Hole KH, DeWeese T, Stensvold A, Tran P, Seierstad T (2020)
Impact of radiation dose on recurrence in high-risk prostate cancer patients
Prostate, 80 (15), 1322-1327
DOI 10.1002/pros.24059, PubMed 33258482

Ryg U, Lilleby W, Hole KH, Lund-Iversen M, Switlyk MD (2020)
Local Recurrence of Prostate Cancer to the Intersphincteric Space: A Case Report
Urology, 140, 18-21
DOI 10.1016/j.urology.2020.03.009, PubMed 32199872

Publications 2019

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Publications 2018

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol, 37 (4), 289.e19-289.e26
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451

Hompland T, Hole KH, Ragnum HB, Aarnes EK, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H (2018)
Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients
Cancer Res, 78 (16), 4774-4785
DOI 10.1158/0008-5472.CAN-17-3806, PubMed 29945958

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 60 (8), 1028-1038
DOI 10.1177/0284185118810977, PubMed 30379559

Tulipan AJ, Vlatkovic L, Malinen E, Brennhovd B, Hole KH, Lie AK, Ragnum HB, Revheim ME, Seierstad T (2018)
Comparison of time curves from dynamic 18F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas
Phys Imaging Radiat Oncol, 7, 51-57
DOI 10.1016/j.phro.2018.09.003, PubMed 33458405

Publications 2017

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Torheim T, Malinen E, Hole KH, Lund KV, Indahl UG, Lyng H, Kvaal K, Futsaether CM (2017)
Autodelineation of cervical cancers using multiparametric magnetic resonance imaging and machine learning
Acta Oncol, 56 (6), 806-812
DOI 10.1080/0284186X.2017.1285499, PubMed 28464746

Publications 2016

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K (2016)
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
World J Surg Oncol, 14, 63
DOI 10.1186/s12957-016-0818-4, PubMed 26940557

Publications 2015

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
DOI 10.1259/bjr.20150097, PubMed 25899892

Switlyk MD, Kongsgaard U, Skjeldal S, Hald JK, Hole KH, Knutstad K, Zaikova O (2015)
Prognostic factors in patients with symptomatic spinal metastases and normal neurological function
Clin Oncol (R Coll Radiol), 27 (4), 213-21
DOI 10.1016/j.clon.2015.01.002, PubMed 25624156

Publications 2014

Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2014)
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
Br J Cancer, 112 (2), 382-90
DOI 10.1038/bjc.2014.604, PubMed 25461803

Raabe NK, Sundfør K, Hole KH, Djupvik LH, Larsen SG, Dueland S (2014)
[High-dose-rate brachytherapy in recurrent rectal cancer after conventional recurrence treatment]
Tidsskr Nor Laegeforen, 134 (20), 1929-30
DOI 10.4045/tidsskr.14.1162, PubMed 25350435

Publications 2013

Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
Radiother Oncol, 107 (1), 117-22
DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024

Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH (2013)
Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer
Radiother Oncol, 107 (2), 178-83
DOI 10.1016/j.radonc.2013.03.017, PubMed 23602370

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T (2013)
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
Acta Oncol, 53 (1), 143-8
DOI 10.3109/0284186X.2013.798428, PubMed 23710697

Publications 2012

Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, Knutstad K, Olsen DR, Seierstad T (2012)
Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance
Eur Radiol, 23 (4), 1158-66
DOI 10.1007/s00330-012-2669-x, PubMed 23114883

Switlyk MD, Hole KH, Skjeldal S, Hald JK, Knutstad K, Seierstad T, Zaikova O (2012)
MRI and neurological findings in patients with spinal metastases
Acta Radiol, 53 (10), 1164-72
DOI 10.1258/ar.2012.120442, PubMed 23047848

Publications 2011

Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954

Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K (2011)
Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies
BJU Int, 110 (2 Pt 2), E69-75
DOI 10.1111/j.1464-410X.2011.10759.x, PubMed 22093091

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-1259
DOI 10.1093/annonc/mdr385, PubMed 21926399

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Publications 2010

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2010)
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
Eur Radiol, 21 (6), 1188-99
DOI 10.1007/s00330-010-2020-3, PubMed 21127880

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Revheim ME, Hole KH, Bruland OS, Haugland HK, Hall KS, Seierstad T (2010)
DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour
Acta Oncol, 50 (1), 148-50
DOI 10.3109/0284186X.2010.516273, PubMed 21110775

Publications 2009

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
Radiother Oncol, 93 (2), 279-84
DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704

Publications 2008

Larsen SG, Wiig JN, Emblemsvaag HL, Grøholt KK, Hole KH, Bentsen A, Dueland S, Vetrhus T, Giercksky KE (2008)
Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging
Colorectal Dis, 11 (7), 759-67
DOI 10.1111/j.1463-1318.2008.01649.x, PubMed 18662240

Publications 2007

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2005

Hoff G, Wiig J, Reed W, Hole KH, Scheistrøen M, Henriksen H (2005)
Short stricture of the rectum regressing on discontinuation of hormone replacement therapy: endoscopic appearance, multiple biopsies and clinical improvement insufficient for diagnosis
Scand J Gastroenterol, 40 (3), 365-7
DOI 10.1080/00365520510011614, PubMed 15932180

Publications 2003

Johannesen TB, Lien HH, Hole KH, Lote K (2003)
Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy
Radiother Oncol, 69 (2), 169-76
DOI 10.1016/s0167-8140(03)00192-0, PubMed 14643954

Publications 1999

Larsen A, Hole KH (1999)
[Life situation of patients with ileoanal anastomosis]
Tidsskr Nor Laegeforen, 119 (26), 3892-5
PubMed 10592747

Page visits: 9919